小儿癫痫丙戊酸钠血药浓度监测的临床研究  

Clinical study of sodium valproate plasma concentration monitoring in children with epilepsy

作　　者：梁国安[1] 姚桂飞[1] 

机构地区：[1]浙江省台州医院儿科,临海317000

出　　处：《海峡药学》2013年第2期248-250,共3页Strait Pharmaceutical Journal

摘　　要：目的通过监测丙戊酸钠血药浓度,为临床合理用药提供参考。方法采用化学发光酶免疫法(CLEIA)测定丙戊酸钠血药浓度,收集98例在丙戊酸钠血药浓度监测下治疗小儿癫痫的临床资料进行分析和统计学处理。结果丙戊酸钠血药浓度低于50mg.L-1、在50～100mg.L-1治疗窗内和高于100mg.L-1的例次百分比分别为28.57%,56.12%和15.31%,血药浓度在不同年龄组及合并不同用药组间相差有显著性意义。结论丙戊酸钠在患儿中的药动学和药效学个体差异较大,监测其血药浓度,实施个体化治疗对提高疗效和保证用药安全具有重要意义。OBJECTIVE To provide a reference for clinical medication by monitoring sodium valproate plasma concentration. METHODS Sodium valproate plasma concentration was determined by Chemiluminescence Enzyme Immunoassay （CLEIA） ,98 children with epilepsy were enrolled. RESULTS The sodium valproate plasma concentration which was lower than 50mg.L^-1 was found in 28.57% of the cases,that which was during 50～100mg.L^-1 was found in56. 12%, and that which was higher than 100mg.L^-1 was found in 15.31%. The sodium valproate plasma concentration has a significant difference during the different age groups and during the combined treatment groups. CONCLUSION Sodium valproate in children with pharmacokinetic and pharmacodynamic has a great individual differences. Monitoring the plasma concentration has a great significance for the implementation of individualized treatment to improve efficacy and to ensure the safe use of drugs.

关 键 词：癫痫 丙戊酸钠 血药浓度监测 

分 类 号：R969.4[医药卫生—药理学]